CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.

24-2058

📡 5G SEP • ETSI Declared

Overview

Case Number 24-2058
Filing Date 2024-07-10
Status Litigation filed
Court Court of Appeals for the Federal Circuit (cafc)
Nature of Suit 830 Patent Infringement (Fed. Qst.)
Cause of Action 35:271 Patent Infringement

Parties

Defendant

AMGEN INC. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

FORMYCON AG NPE (Individual / Inventor)

Represented By

0 Attorneys Listed
No attorneys available

SAMSUNG BIOEPIS CO., LTD. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

BIOCON BIOLOGICS INC. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

AMGEN USA, INC. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

MYLAN PHARMACEUTICALS INC. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff - Appellee

REGENERON PHARMACEUTICALS, INC. Operating Company

Represented By

1 Attorneys Listed

David I. Berl, Esq.

Williams & Connolly LLP

680 Maine Avenue SW, 20024

Defendant - Appellant

CELLTRION, INC. Operating Company

Represented By

1 Attorneys Listed

Robert V. Cerwinski

Gemini Law LLP

Suite 6n, 40 W 24th Street

Court & Judges

Court

Court of Appeals for the Federal Circuit (cafc)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

No Co-Pending Disputes Detected in Current Index

There are no other active filings for this patent family across our indexed PTAB, U.S. Court, UPC, or EPO databases.

Standard Essential Patent (SEP) & FRAND Intelligence

5G SEP • ETSI Declared High-Probability SEP Action

Essential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation

FRAND Encumbered
Essential Standard 5G NR Generation: 5G
Standard Setting Org (SSO) ETSI / 3GPP Essential specification under ETSI / 3GPP governance
FRAND Commitment Committed Fair, Reasonable & Non-Discrim.
Known Patent Pools Avanci / Sisvel / Via Licensing Coverage Applicable Declarant: Samsung

Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)

Permanent Injunction Restricted

Asserted by recognized SEP declarant; CJEU Huawei v. ZTE restrictions apply.

✓ Patentee bound by SSO IPR Policy (ETSI Annex 6 / IEEE Patent Policy).
✓ Right to demand global FRAND portfolio determination.
✓ Non-discrimination defense: check licensing terms offered to competing implementers.

Patents Involved

No asserted patent numbers detected in initial docket filings yet.

Docket Entries

(0 total)

Docket documents haven't synced yet — they're refreshed once a day. Check back soon, or open the CasLoc app for the live view in the meantime.

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc